---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269548"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:56:35.107276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MindMed Q3 cash $209M, raises $242.8M; MM120 Phase 3 GAD/MDD readouts on track for 2026

## Summary
- Cash, cash equivalents and investments of $209.1M at Sept 30, 2025; net proceeds of $242.8M from Oct 31 offering extend runway into 2028.
- R&D expenses $31.0M in Q3 2025 vs $17.2M in Q3 2024, driven by MM120 program costs.
- Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) 2H 2026.
- Phase 3 Emerge (MDD) topline data accelerated to mid-2026 (from 2H 2026); Ascend (MDD) to initiate mid-2026.
- Phase 2a of MM402 for ASD to start Q4 2025; MM120 Phase 2b published in JAMA.

## SEC filing metadata
- accession: 0001193125-25-269548
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312525269548/0001193125-25-269548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312525269548/mnmd-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269548
- JSON: https://secwatch.observer/filing/0001193125-25-269548.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.